A Phase 2 interventional study of SGN-15 (cBR96-doxorubicin immunoconjugate) and Taxotere (docetaxel) in Prostatic Neoplasms, sponsored by Seagen Inc.. Completed at 11 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-10-24.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies testing docetaxel in Prostatic Neoplasms — 15 open to participants now, 24 under way, 10 of them phase 3. Docetaxel · Prostatic Neoplasms.
Among the 193 studies testing docetaxel in Prostatic Neoplasms, this one is the 35th largest by enrollment of the 185 interventional ones that give a count, is one of 5 that started in 2000, is one of 104 in phase 2, and was the 15th registered.
7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →15 of the 193 studies testing docetaxel in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+ · Men only
Charles Drew University of Medicine and Science · Sites in United States
Ages 18+ · Men only
Instituto do Cancer do Estado de São Paulo · Sites in Brazil
Ages 18+ · Men only
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD · Sites in France, Germany, Italy and 2 more countries
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 131 · Phase 3 34 · Phase 4 1
First in 1998; this study’s year is marked. 5 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is above the median of 60 across 5,354 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 39 across the 185 interventional studies. Of the 143 that completed or were terminated, 53 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 193 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
42 studies in Prostatic Neoplasms by Pfizer: 2 open now, 8 under way, 5 of them phase 3. Of 33 finished, 28 (85%) have results posted.
Among the 42 studies in Prostatic Neoplasms by Pfizer, this one is the 17th largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2000, is one of 10 in phase 2, and was the 3rd registered.
Pfizer’s Prostatic Neoplasms studies by the year they started, since 1998.
6 of the studies testing docetaxel in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT03574571Phase 3Memorial Sloan Kettering Cancer CenterA Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer | 2027-04-01 |
| NCT06480110Rigshospitalet, DenmarkEbastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer | 2026-12-01 |
| NCT04633252National Cancer Institute (NCI)A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer | 2026-12-31 |
| NCT04015622British Columbia Cancer AgencyPROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA | 2027-01-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 193 studies testing docetaxel in Prostatic Neoplasms, from their registry updates:
Among Pfizer’s 42 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
SGN-15 is being investigated for therapy of patients with prostate cancer in combination with the cytotoxic agent, Taxotere. The study is an open label, randomized phase II study for patients with documented hormone refractory prostate cancer who have not had any prior therapy with Taxotere or Novantrone. Both SGN-15 and Taxotere will be administered weekly over two 6 week courses separated by a 2 week rest period.
The purpose of this study is to evaluate a new class of biologic agent, the monoclonal antibody (mAb) drug conjugate SGN-15 (cBR96 - Doxorubicin immunoconjugate), used in combination with the taxane agent, TAXOTERE (docetaxel) as a strategy for targeting advanced stage, hormone refractory prostate carcinoma (HRPC). This is a randomized, open label, phase II study evaluating the immunoconjugate SGN-15 in combination with the taxane TAXOTERE in comparison to TAXOTERE alone in patients with HRPC. Based on a previous phase I study of the SGN-15/TAXOTERE combination, the weekly dose of SGN-15 will be 200 mg/m2 and the weekly dose of TAXOTERE will be 35 mg/m2. The schedule of administration for both agents will be weekly, with SGN-15 administered prior to the TAXOTERE in the patients treated with the combination. A single course of therapy will be defined as 6 weekly doses followed by a 2 week rest period for a total of 8 weeks. The study will perform an interim analysis of the data after 80 patients have completed two courses. Patients should be treated for a minimum of 2 courses of therapy. Additionally, for patients who remain eligible and have experienced tolerable levels of drug toxicity, repeat dosing with subsequent cycles is possible. Patients will be removed from study if there is evidence of tumor progression or intolerable toxicity. Follow-up assessments include adverse event reporting, clinical laboratory studies, and quality of life (QOL) assessment using a validated QOL instrument.
BRIEF:
Patients must have confirmed prostate cancer, which is to hormone therapy. There must be evidence of advancing disease, determined by increasing bidimensional or unidimensional measurable tumor or an increasing PSA with documented disease.
Patients must have Lewis(Y) antigen expression documented by immunohistochemistry on archived or fresh tumor specimen.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The record gives a start of Oct 2000 and a completion of Jul 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: BR96-Doxorubicin Immunoconjugate · Docetaxel